Ferraris A M, Canepa L, Mareni C, Baule G, Meloni T, Salvidio E, Forteleoni G, Gaetani G F
Blood. 1983 Jul;62(1):177-9.
A patient with erythroleukemia and heterozygous for the Mediterranean variant of the X-linked enzyme glucose-6-phosphate dehydrogenase (G6PD) was studied to determine the number and type of progenitor cells in which the disease arose. G6PD mosaicism was assessed by the different rate of utilization of 2-deoxy-glucose-6-phosphate (2dG6P) by normal and Mediterranean variants of G6PD. Erythroleukemia is established as a clonal disease involving a precursor cell common to the erythroid and myeloid lines. After intensive chemotherapy, restoration of nonmonoclonal hemopoiesis is achieved, as indicated by the reappearance of the mosaic phenotype in hemopoietic cell populations.
对一名患有红白血病且为X连锁酶葡萄糖-6-磷酸脱氢酶（G6PD）地中海变异型杂合子的患者进行了研究，以确定发生该疾病的祖细胞数量和类型。通过G6PD正常变异型和地中海变异型对2-脱氧葡萄糖-6-磷酸（2dG6P）的不同利用速率来评估G6PD镶嵌现象。红白血病被确认为一种克隆性疾病，涉及红系和髓系共有的前体细胞。强化化疗后，造血细胞群体中镶嵌表型的再次出现表明实现了非单克隆造血的恢复。
